Open Access
Issue
Published:
12 December 2023
Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention
Download citation
52
Views
4
Downloads
0
Crossref
N/A
WoS
N/A
Scopus
N/A
CSCD
The importance of uncommon/rare oncogenic drivers in non‐small cell lung cancer (NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers, while present in a significant proportion of NSCLC patients, remain a challenge for diagnosis and therapeutic targeting. In the never‐smokers/low smokers category with mutations such as EGFR and HER2, the efficacy of immune checkpoint inhibitors (ICIs) remains suboptimal, attributed to lower PD‐L1 expression and tumor mutation burden (TMB). However, heavy smokers, often with mutations like KRAS, may derive benefits from ICIs, as supported by trials like CheckMate‐057. With the complex landscape of these drivers and their clinical implications, the summit culminated in six pivotal consensus points, aiming to guide future research and clinical decisions. Despite the advancements, the detection, interpretation, and therapeutic strategies involving these drivers necessitate further exploration and standardization.
menu
Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention
Abstract
The importance of uncommon/rare oncogenic drivers in non‐small cell lung cancer (NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers, while present in a significant proportion of NSCLC patients, remain a challenge for diagnosis and therapeutic targeting. In the never‐smokers/low smokers category with mutations such as EGFR and HER2, the efficacy of immune checkpoint inhibitors (ICIs) remains suboptimal, attributed to lower PD‐L1 expression and tumor mutation burden (TMB). However, heavy smokers, often with mutations like KRAS, may derive benefits from ICIs, as supported by trials like CheckMate‐057. With the complex landscape of these drivers and their clinical implications, the summit culminated in six pivotal consensus points, aiming to guide future research and clinical decisions. Despite the advancements, the detection, interpretation, and therapeutic strategies involving these drivers necessitate further exploration and standardization.
References(81)
Fang W, Huang Y, Hong S, Zhang Z, Wang M, Gan J, et al. EGFR exon 20 insertion mutations and response to osimertinib in non‐small‐cell lung cancer. BMC Cancer. 2019;19(1):595. https://doi.org/10.1186/s12885-019-5820-0
Mao L, Zhao W, Li X, Zhang S, Zhou C, Zhou D, et al. Mutation spectrum of EGFR from 21,324 Chinese patients with non‐small cell lung cancer (NSCLC) successfully tested by multiple methods in a CAP‐accredited laboratory. Pathol Oncol Res. 2021;27:602726. https://doi.org/10.3389/pore.2021.602726
Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611–25. https://doi.org/10.1200/JCO.21.01626
Yang G, Yang Y, Liu R, Li W, Xu H, Hao X, et al. First‐line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2‐altered NSCLC: a retrospective real‐world POLISH study. Ther Adv Med Oncol. 2022;14:17588359221082339. https://doi.org/10.1177/17588359221082339
Jonna S, Feldman RA, Swensen J, Gatalica Z, Korn WM, Borghaei H, et al. Detection of NRG1 gene fusions in solid tumors. Clin Cancer Res. 2019;25(16):4966–72. https://doi.org/10.1158/1078-0432.CCR-19-0160
Chinese Society of Pathology, Pathology Quality Control Center, Lung Cancer Group of Chinese Medical Association Chinese Society of Oncology, et al. Chinese expert consensus on clinical practice of MET detection in non‐small cell lung cancer. Chinese expert consensus on clinical practice of MET detection in non‐small cell lung cancer. Chin J Pathol 2022;51(11):1094–103.
Yu Y, Ding Z, Zhu L, Teng H. Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases. Springer Plus. 2016;5(1):894. https://doi.org/10.1186/s40064-016-2607-5
Gou LY, Wu YL. Prevalence of driver mutations in non‐small‐cell lung cancers in the People’s Republic of China. Lung Cancer. 2014;5:1–9. https://doi.org/10.2147/LCTT.S40817
Chinese Society of Pathology, Pathology Quality Control Center, Lung Cancer Group of Chinese Medical Association Chinese Society of Oncology. Guidelines on clinical practice of molecular tests in non‐small cell lung cancer in China, Chin. J Pathol 2021;50(4):323–32.
Lung Cancer Professional Group of Chinese Anti‐Cancer Association Pathology Specialized Committee. Expert consensus on diagnosis of ROS1 gene fusion‐positive non‐small cell lung cancer. Chin J Pathol 2018;47(4):248–51.
Molecular Pathology Collaboration Group of Tumor Pathology Committee of Chinese Anti‐Cancer Association. Molecular Pathology Group of Chinese Society of Pathology, Pathology Quality Control Center. Expert consensus on clinical practice of RET fusion detection in non‐small cell lung cancer in China. Chin J Pathol 2021;50(6):583–91.
Ren S, Wang J, Ying J, Mitsudomi T, Lee D, Wang Z, et al. Consensus for HER2 alterations testing in non‐small‐cell lung cancer. ESMO Open. 2022;7(1):100395. https://doi.org/10.1016/j.esmoop.2022.100395
Xu C, Si L, Wang W, Li Z, Song Z, Wang Q, et al. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China. Thorac Cancer. 2022;13(21):3084–97. https://doi.org/10.1111/1759-7714.14644
Zhang S, Wang W, Xu C, Zhang Y, Cai X, Wang Q, et al. Chinese expert consensus on the diagnosis and treatment of HER2‐altered non‐small cell lung cancer. Thorac Cancer. 2023;14(1):91–104. https://doi.org/10.1111/1759-7714.14743
D'Arcangelo M, D'Incecco A, Cappuzzo F. Rare mutations in non‐small‐cell lung cancer. Future Oncol Lond Engl 2013;9(5):699–711. https://doi.org/10.2217/fon.13.16
Guo Y, Cao R, Zhang X, Huang L, Sun L, Zhao J, et al. Recent progress in rare oncogenic drivers and targeted therapy for non‐small cell lung cancer. Onco Targets Ther. 2019;12:10343–60. https://doi.org/10.2147/OTT.S230309
Experts from the RATICAL study (ALK testing in Chinese advanced non‐small cell lung cancer patients: a national‐wide multicenter prospective real world data study), MO lecular Pathology Committee of Chinese Society of Pathology. Expert consensus on clinical practice of ALK fusion detection in non‐small cell lung cancer in China. Chin J Pathol 2019;48(12):913–20.
Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn M, et al. ESMO expert consensus statements on the management of EGFR mutant non‐small‐cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol 2022;33(5):466–87. https://doi.org/10.1016/j.annonc.2022.02.003
Lung Cancer Professional Committee of Chinese Anti‐Cancer Association. Expert consensus on the diagnosis and treatment in advanced non‐small cell lung cancer with BRAF mutation in China, Chin. JAMA Oncol 2023;45(4):279–90.
Solomon JP, Yang SR, Choudhury NJ, Ptashkin RN, Eslamdoost N, Falcon CJ, et al. Bioinformatically expanded next‐generation sequencing analysis optimizes identification of therapeutically relevant MET copy number alterations in >50,000 tumors. Clin Cancer Res Off J Am Assoc Cancer Res 2022;28(21):4649–59. https://doi.org/10.1158/1078-0432.CCR-22-1321
Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol Off J U S Can Acad Pathol Inc. 2020;33(1):38–46. https://doi.org/10.1038/s41379-019-0324-7
Davies KD, Lomboy A, Lawrence CA, Yourshaw M, Bocsi GT, Camidge DR, et al. DNA‐based versus RNA‐based detection of MET exon 14 skipping events in lung cancer. J Thorac Oncol 2019;14(4):737–41. https://doi.org/10.1016/j.jtho.2018.12.020
Ju S, Cui Z, Hong Y, Wang X, Mu W, Xie Z, et al. Detection of multiple types of cancer driver mutations using targeted RNA sequencing in non‐small cell lung cancer. Cancer. 2023;129(15):2422–30. https://doi.org/10.1002/cncr.34804
Chen J, Yang H, Teo ASM, Amer LB, Sherbaf FG, Tan CQ, et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet 2020;52(2):177–86. https://doi.org/10.1038/s41588-019-0569-6
Chinese Society of Clinical Oncology. Expert Committee on Non‐small Cell Lung Cancer. Chinese expert consensus on next generation sequencing diagnosis for non‐small cell lung cancer (2020 edition). Chin J Lung Cancer. 2020;23(9):741–61.
Rao C, Nie L, Wu X, Miao X, Chen T, Chen L, et al. Case report: durable response to alectinib in ALK‐rearranged lung adenocarcinoma with acquired, crizotinib‐resistant ALK C1156F mutation. Front Oncol 2022;12:915502. https://doi.org/10.3389/fonc.2022.915502
Shen CI, Chiang CL, Shiao TH, Luo YH, Chao HS, Huang HC, et al. Real‐world evidence of the intrinsic limitations of PCR‐based EGFR mutation assay in non‐small cell lung cancer. Sci Rep 2022;12(1):13566. https://doi.org/10.1038/s41598-022-17394-7
Tan AC, Lai GGY, Tan GS, Poon SY, Doble B, Lim TH, et al. Utility of incorporating next‐generation sequencing (NGS) in an Asian non‐small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost‐effectiveness analysis. Lung Cancer Amsterdam Neth. 2020;139:207–15. https://doi.org/10.1016/j.lungcan.2019.11.022
Vanderpoel J, Stevens AL, Emond B, Lafeuille MH, Hilts A, Lefebvre P, et al. Total cost of testing for genomic alterations associated with next‐generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non‐small cell lung cancer. J Med Econ 2022;25(1):457–68. https://doi.org/10.1080/13696998.2022.2053403
Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of American pathologists. J Mol Diagn 2017;19(1):4–23. https://doi.org/10.1016/j.jmoldx.2016.10.002
Maslin‐Prothero S. The role of the multidisciplinary team in recruiting to cancer clinical trials. Eur J Cancer Care. 2006;15(2):146–54. https://doi.org/10.1111/j.1365-2354.2005.00625.x
Taberna M, Gil Moncayo F, Jané‐Salas E, Antonio M, Arribas L, Vilajosana E, et al. The multidisciplinary team (MDT) approach and quality of care. Front Oncol 2020;10. https://doi.org/10.3389/fonc.2020.00085
Denton E, Conron M. Improving outcomes in lung cancer: the value of the multidisciplinary health care team. J Multidiscip Healthc 2016;9:137–44. https://doi.org/10.2147/JMDH.S76762
van der Velden DL, van Herpen C, van Laarhoven H, Smit E, Groen H, Willems S, et al. Molecular Tumor Boards: current practice and future needs. Ann Oncol 2017;28(12):3070–5. https://doi.org/10.1093/annonc/mdx528
Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, Ferguson ME, et al. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget. 2016;7(35):56491–500. https://doi.org/10.18632/oncotarget.10606
Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, et al. Real‐world data from a molecular tumor board demonstrates improved outcomes with a precision N‐of‐One strategy. Nat Commun 2020;11(1):4965. https://doi.org/10.1038/s41467-020-18613-3
Larson KL, Huang B, Weiss HL, Hull P, Westgate PM, Miller RW, et al. Clinical outcomes of molecular tumor boards: a systematic review. JCO Precis Oncol 2021;5:1122–32. https://doi.org/10.1200/PO.20.00495
Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, et al. Molecular tumor board: the university of California‐San diego moores cancer center experience. Oncol. 2014;19(6):631–6. https://doi.org/10.1634/theoncologist.2013-0405
LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, et al. Pilot trial of selecting molecularly guided therapy for patients with non‐V600 BRAF‐mutant metastatic melanoma: experience of the SU2C/MRA melanoma dream team. Mol Cancer Therapeut 2015;14(8):1962–71. https://doi.org/10.1158/1535-7163.MCT-15-0153
Martínez‐Jiménez F, Muiños F, Sentís I, Deu‐Pons J, Reyes‐Salazar I, Arnedo‐Pac C, et al. A compendium of mutational cancer driver genes. Nat Rev Cancer. 2020;20(10):555–72. https://doi.org/10.1038/s41568-020-0290-x
Krawczyk P, Jassem J, Wojas‐Krawczyk K, Krzakowski M, Dziadziuszko R, Olszewski W. New genetic technologies in diagnosis and treatment of cancer of unknown primary. Cancers. 2022;14(14):3429. https://doi.org/10.3390/cancers14143429
Wahida A, Buschhorn L, Fröhling S, Jost PJ, Schneeweiss A, Lichter P, et al. The coming decade in precision oncology: six riddles. Nat Rev Cancer. 2023;23(1):43–54. https://doi.org/10.1038/s41568-022-00529-3
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK‐positive non‐small‐cell lung cancer. N Engl J Med 2017;377(9):829–38. https://doi.org/10.1056/NEJMoa1704795
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First‐line lorlatinib or crizotinib in advanced ALK‐positive lung cancer. N Engl J Med 2020;383(21):2018–29. https://doi.org/10.1056/NEJMoa2027187
Drilon A, Chiu CH, Fan Y, Cho BC, Lu S, Ahn MJ, et al. Long‐term efficacy and safety of entrectinib in ROS1 fusion‐positive NSCLC. JTO Clin Res Rep 2022;3(6):100332. https://doi.org/10.1016/j.jtocrr.2022.100332
Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 2021;384(25):2371–81. https://doi.org/10.1056/NEJMoa2103695
Drilon A, Oxnard GR, Tan DSW, Loong HH, Johnson M, Gainor J, et al. Efficacy of selpercatinib in RET fusion‐positive non‐small‐cell lung cancer. N Engl J Med 2020;383(9):813–24. https://doi.org/10.1056/NEJMoa2005653
Gainor JF, Rizvi H, Aguilar EJ, Skoulidis F, Yeap B, Naidoo J, et al. Clinical activity of programmed cell death 1 (PD‐1) blockade in never, light, and heavy smokers with non‐small‐cell lung cancer and PD‐L1 expression ≥50. Ann Oncol Off J Eur Soc Med Oncol 2020;31(3):404–11. https://doi.org/10.1016/j.annonc.2019.11.015
Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, et al. Expression of PD‐1 and its ligands, PD‐L1 and PD‐L2, in smokers and never smokers with KRAS‐mutant lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015;10(12):1726–35. https://doi.org/10.1097/JTO.0000000000000687
Wang X, Ricciuti B, Nguyen T, Li X, Rabin MS, Awad MM, et al. Association between smoking history and tumor mutation burden in advanced non‐small cell lung cancer. Cancer Res. 2021;81(9):2566–73. https://doi.org/10.1158/0008-5472.CAN-20-3991
Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, et al. Oncogene‐specific differences in tumor mutational burden, PD‐L1 expression, and outcomes from immunotherapy in non‐small cell lung cancer. J Immunother Cancer. 2021;9(8):e002891. https://doi.org/10.1136/jitc-2021-002891
Borghaei H, Paz‐Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non‐small‐cell lung cancer. N Engl J Med 2015;373(17):1627–39. https://doi.org/10.1056/NEJMoa1507643
Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD‐1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 2017;23(12):3012–24. https://doi.org/10.1158/1078-0432.CCR-16-2554
Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, et al. Diminished efficacy of programmed death‐(ligand)1 inhibition in STK11‐ and KEAP1‐mutant lung adenocarcinoma is affected by KRAS mutation status. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2022;17(3):399–410. https://doi.org/10.1016/j.jtho.2021.10.013
Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019;30(8):1321–8. https://doi.org/10.1093/annonc/mdz167
Guisier F, Dubos‐Arvis C, Viñas F, Doubre H, Ricordel C, Ropert S, et al. Efficacy and safety of anti‐PD‐1 immunotherapy inPatients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01‐2018. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2020;15(4):628–36. https://doi.org/10.1016/j.jtho.2019.12.129
Murciano‐Goroff YR, Pak T, Mondaca S, Flynn JR, Montecalvo J, Rekhtman N, et al. Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non‐V600 altered lung cancers. Br J Cancer. 2022;126(6):889–98. https://doi.org/10.1038/s41416-021-01679-1
Dudnik E, Peled N, Nechushtan H, Wollner M, Onn A, Agbarya A, et al. BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check‐point inhibitors. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13(8):1128–37. https://doi.org/10.1016/j.jtho.2018.04.024
Otano I, Ucero AC, Zugazagoitia J, Paz‐Ares L. At the crossroads of immunotherapy for oncogene‐addicted subsets of NSCLC. Nat Rev Clin Oncol 2023;20(3):143–59. https://doi.org/10.1038/s41571-022-00718-x
Mansinho A, Fernandes RM, Carneiro AV. Histology‐agnostic drugs: a paradigm shift‐a narrative review. Adv Ther 2023;40(4):1379–92. https://doi.org/10.1007/s12325-022-02362-4
Middleton G, Crack LR, Popat S, Swanton C, Hollingsworth S, Buller R, et al. The National Lung Matrix Trial: translating the biology of stratification in advanced non‐small‐cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol 2015;26(12):2464–9. https://doi.org/10.1093/annonc/mdv394
Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. 2020;583(7818):807–12. https://doi.org/10.1038/s41586-020-2481-8
Li BT, Daly B, Gospodarowicz M, Bertagnolli MM, Brawley OW, Chabner BA, et al. Reimagining patient‐centric cancer clinical trials: a multi‐stakeholder international coalition. Nat Med 2022;28(4):620–6. https://doi.org/10.1038/s41591-022-01775-6
Liu SM, Yan HH, Wei XW, Lu C, Dong XR, Du Y, et al. Biomarker‐driven studies with multi‐targets and multi‐drugs by next‐generation sequencing for patients with non‐small‐cell lung cancer: an open‐label, multi‐center, phase Ⅱ adaptive umbrella trial and a real‐world observational study (CTONG1702&CTONG1705). Clin Lung Cancer. 2022;23(7):e395–9. https://doi.org/10.1016/j.cllc.2022.05.009
Liu SYM, Tu HY, Wei XW, Yan HH, Dong XR, Cui JW, et al. First‐line pyrotinib in advanced HER2‐mutant non‐small‐cell lung cancer: a patient‐centric phase 2 trial. Nat Med 2023;29(8):2079–86. https://doi.org/10.1038/s41591-023-02461-x
Goldstraw P, Chansky K, Crowley J, Rami‐Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016;11(1):39–51. https://doi.org/10.1016/j.jtho.2015.09.009
NSCLC Meta‐analysis Collaborative Group. Preoperative chemotherapy for non‐small‐cell lung cancer: a systematic review and meta‐analysis of individual participant data. Lancet. 2014;383(9928):1561–71. https://doi.org/10.1016/S0140-6736(13)62159-5
NMA C Group, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non‐small‐cell lung cancer: two meta‐analyses of individual patient data. Lancet Lond Engl2010;375(9722):1267–77. https://doi.org/10.1016/S0140-6736(10)60059-1
Zhang C, Li SL, Nie Q, Dong S, Shao Y, Yang X, et al. Neoadjuvant crizotinib in resectable locally advanced non‐small cell lung cancer with ALK rearrangement. J Thorac Oncol 2019;14(4):726–31. https://doi.org/10.1016/j.jtho.2018.10.161
Zenke Y, Yoh K, Sakakibara‐Konishi J, Daga H, Hosomi Y, Nogami N, et al. P1.18‐04 neoadjuvant ceritinib for locally advanced non‐small cell lung cancer with ALK rearrangement: SAKULA trial. J Thorac Oncol 2019;14(10):S626–7. https://doi.org/10.1016/j.jtho.2019.08.1320
Zhou N, Li T, Liang M, Ren F, Ni H, Liu W, et al. Use of pralsetinib as neoadjuvant therapy for non‐small cell lung cancer patient with RET rearrangement. Front Oncol 2022;12:848779. https://doi.org/10.3389/fonc.2022.848779
Sørensen JB, Urbanska E, Melchior L, Santoni‐Rugiu E. P46.03 targeting ROS1 gene rearrangement by crizotinib as neoadjuvant treatment before definitive radiotherapy in locally advanced NSCLC. J Thorac Oncol 2021;16(10):S1094. https://doi.org/10.1016/j.jtho.2021.08.489
Solomon BJ, Ahn JS, Barlesi F, Dziadziuszko R, Nishio M, Shaw AT, et al. ALINA: a phase Ⅲ study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–ⅢA anaplastic lymphoma kinase‐positive (ALK+) non‐small cell lung cancer (NSCLC). J Clin Oncol 2019;37(15_Suppl l):TPS8569. https://doi.org/10.1200/jco.2019.37.15_suppl.tps8569
Tsuboi M, Goldman JW, Wu YL, Johnson ML, Paz‐Ares L, Yang JCH, et al. LIBRETTO‐432, a phase Ⅲ study of adjuvant selpercatinib or placebo in stage ⅠB‐ⅢA RET fusion‐positive non‐small‐cell lung cancer. Future Oncol Lond Engl 2022;18(28):3133–41. https://doi.org/10.2217/fon-2022-0656
Lee JM, Sepesi B, Toloza EM, Lin J, Pass H, Johnson B, et al. EP02.04‐005 phase Ⅱ NAUTIKA1 study of targeted therapies in stage Ⅱ‐Ⅲ NSCLC: preliminary data of neoadjuvant alectinib for ALK+ NSCLC. J Thorac Oncol 2022;17(9):S233–4. https://doi.org/10.1016/j.jtho.2022.07.390
Wang Y, Zhai H, Wang J, Mao T, Ji C, Bao F, et al. Study protocol of an open‐label prospective phase Ⅱ umbrella study of precise neoadjuvant therapy for patients with stage Ⅱ‐ⅢB resectable non‐small cell lung cancer (PURPOSE). Front Oncol 2022;12:1052774. https://doi.org/10.3389/fonc.2022.1052774
Publication history
Copyright
Acknowledgements
Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (2017B030314120, Yi‐Long Wu), Guangdong Provincial Peoples Hospital Scientific Research Fundsfor Leading MedicalTalentsin Guangdong Province (KJ012019426, Yi‐Long Wu), the National Natural Science Foundation of China (Grant No.82072562, Qing Zhou).
Rights and permissions
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
FEEDBACK 
TOP